NCT01913639View on ClinicalTrials.gov

FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Esophageal CancerGastric Cancer
Interventions
DRUG

Regorafenib

DRUG

5-Fluorouracil

DRUG

Leucovorin

DRUG

Oxaliplatin

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Unknown

Memoral Sloan Kettering Cancer Center, Basking Ridge

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01913639 - FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer | Biotech Hunter | Biotech Hunter